2025 Sponsors

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhyloCode™ Panels and Photocycle®, Phen Imager® Fusion, and Phen Imager HT Instruments. For more information, visit https://www.akoyabio.com/

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. For more information, visit https://guardanthealth.com/

Lunit develops AI-powered medical image analysis software via cutting-edge deep learning technology. Our Lunit SCOPE product suite helps researchers and clinicians make accurate and efficient decisions through data-driven imaging biomarkers. Lunit SCOPE IO is our AI-powered analyzer of the tumor microenvironment, purely from H&E, for quantitative immune phenotyping and beyond. Peer reviewed studies employing SCOPE IO have been published in the Journal of Clinical Oncology, Clinical Cancer Research, NPJ Precision Oncology, and more. Lunit SCOPE IHC is our AI-powered analyzer of IHC targets including PD-L1, HER2, and more. Lunit SCOPE IHC currently powers all PD-L1 scoring for Guardant Health’s Galaxy PD-L1 tissue testing. Lunit works with the world’s leading biopharmaceutical companies, CROs, and clinical labs to develop and deploy the next generation of oncology therapeutic biomarkers. For more information, visit https://www.lunit.io/en

NeoGenomics specializes in premier cancer solutions. We partner with pharmaceutical clients from discovery to commercialization with our broad oncology testing capabilities powered by in-house scientific expertise and dedicated project support teams. Our clients benefit from our state-of-the-art molecular technology, from whole exome sequencing, whole transcriptome sequencing, HLA typing, and the proprietary MultiOmyx™ high-order multiplexing methodology. We are the trusted experts with over 20 years of experience helping navigate the increasingly complex cancer landscape. For more information, visit https://neogenomics.com.

Coherus is a commercial-stage innovative oncology company with a US FDA approved PD-1 inhibitor, LOQTORZI, as well as two proprietary pipeline products; a first in class Phase 2 anti-IL-27, casdozokitug, being developed in combination with LOQTORZI for the treatment of liver and lung cancer and a highly selective cytolytic CCR8 antibody, CHS-114, being developed in combination with LOQTORZI in head and neck squamous cell carcinoma and gastric cancer. Clinical data readouts are occurring in 2025 supporting these studies with safety, initial efficacy and proof of mechanism that builds momentum with initial key data readouts for these studies being projected to occur in H1 2026.LOQTORZI is the only FDA-approved treatment for metastatic/recurrent locally advanced nasopharyngeal carcinoma in all lines of therapy and the new standard of care. LOQTORZI was launched in the U.S. in Q1 2024 and is expected to reach $150M to $200M in sales within three to four years.In addition, LOQTORZI is being evaluated in two pivotal clinical trials, which could expand the label into additional indications in the U.S.. The first is in combination with anti-BTLA, tifcemalimab, in small cell lung cancer sponsored by Junshi BioSciences and the second is planned to open in the 2H of 2025 in combination with INO-3112 in locally advanced high-risk HPV positive head and neck cancer.Coherus is focused on expanding the indications for LOQTORZI in combination with other agents to extend patient survival across tumor types. The market opportunity addressed by current pipeline candidates is up to $15B annually. For more information please visit https://www.coherus.com/.

AdhereTech is transforming clinical trial adherence with the Aidia System, an innovative overcap smart device that delivers real-time data without requiring apps, Wi-Fi, or syncing. Unlike traditional methods such as pill counting, journals, or video capture, Aidia provides precise, timestamped adherence tracking while placing virtually no burden on patients or sites. Patients use the Aidia-enabled bottle just like any standard medication bottle, with no change to their routine. The device connects automatically via cellular signal, is fully reusable, and requires no additional stability testing. Clinical teams benefit from customizable alerts, remote reprogramming, and proactive support from AdhereTech’s live monitoring team. By ensuring consistent dosing behavior, Aidia helps sponsors strengthen efficacy signals, maintain regulatory compliance, and avoid costly setbacks due to non-adherence. Learn more at https://adheretech.com. 

Sponsors, sites, and contract research organizations (CROs) rely on Advarra to ensure safety, quality, and efficiency throughout the clinical trial lifecycle. Our unmatched research review services expertise and innovative site and sponsor technology are trusted by industry leaders including the top 50 global biopharma sponsors, the top 15 CROs, over 3,500 institutions, hospitals, health systems, and academic medical centers and 50,000 site investigators worldwide. Our unique portfolio of technology and services powers clinical research to make it safer, smarter and faster. For more information, go to https://www.advarra.com/

Immunai's engineering-first platform maps the immune system for the discovery and augmentation of novel therapeutics, through single-cell sequencing, functional genomics, big data and ML. Immunai holds a successful track record of partnering with leading pharmaceutical and biotech companies, academic institutions and hospitals to optimize their preclinical and clinical decision-making. To learn more, please visit https://www.immunai.com/

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans. For more information, go to https://onc.ai/

Precision for Medicine is the first global, precision-medicine, clinical research organization and a leader in complex clinical development. Our clients benefit from advanced technologies and new approaches that compress timelines, gain efficiencies and increase the probability of approval. Under one global roof, Precision has worldwide CRO services, integrated sophisticated biomarker capabilities, technical manufacturing solutions and more. With 7 specialty labs and 3500+ professionals worldwide, we help clients accelerate life-changing treatments and propel medicine forward. For more information, visit https://www.precisionformedicine.com/

Scimega is a niche Canadian oncology CRO acting in Canada within the context of global cutting-edge oncology trials sponsored by mid-size and smaller biotechs. Skilled in collaborative vendor teaming, Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. With an optimal operations design robust enough to address an ever-changing clinical trial landscape, Scimega’s team of Lean Coached oncology experts go above-and-beyond to provide: Local, full-time, permanent hires for exceptional staff quality; An extensive network of Canadian Investigator Sites that frequently emerge among top enrollers, and are activated 50% faster than average for global studies; Optimal site engagement to maximize quality, timely data entry and query resolution; Robust and Lean Scimega methodology and processes are supported by current technology to keep every trial this CRO monitors on the Lean trajectory.

To learn more about the Canadian opportunity or explore an expansion with Scimega, please visit: https://scimega.com/

TD2 provides innovative services for improved and accelerated development of medicines for cancer. Our team has deep experience and understanding in drug development. Preclinical development, combined with regulatory affairs expertise, guides customized clinical trial design and execution. Our capabilities encourage the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. For more information, go to www.td2inc.com

Aixial is a global, therapeutically focused Clinical Research Organization with extensive expertise in the immuno-oncology therapeutic area. Since 2002, the company has been a trusted partner in the rapidly evolving immuno-oncology field.

Aixial’s team is experienced in managing the complexities of immuno-oncology trials, from Phase I first in human through post marketing.  By offering flexible clinical trial services we accelerate development by augmenting client teams with experts, enabling robust clinical outcomes, and helping clients navigate the challenges of bringing new cancer therapies to market. For more information, visit https://www.aixialgroup.com/

Champions Oncology is a global preclinical research and clinical specialty testing services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Champions is a fully regulated clinical laboratory that can validate assays to GCLP compliance with CAP accreditation and CLIA certification. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide.  For more information, please visit www.ChampionsOncology.com.

Leading scientists and researchers turn to Flywheel to accelerate their work and collaborate with ease. Our medical imaging AI platform streamlines the massive tasks of data discovery, aggregation, and curation; automates research workflows; and scales on demand. For more information, visit https://flywheel.io/.

At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy sequence data in studies around the globe. Our microarrays also provide accurate, high-throughput genotyping for a range of applications. The innovative products that we provide are facilitating breakthroughs in many scientific areas, including oncology, reproductive health, genetic disease, precision medicine, agriculture, microbiology, and beyond. The progress we see being made in genomics inspires us to push the boundaries of what is possible so we can create the next generation of genomics solutions. For more information, go to https://www.illumina.com/

ImmunAware is dedicated to advancing immunological research, particularly in the areas of high-quality reagents and services. Founded by scientists from the University of Copenhagen, we have a wealth of experience in MHC biochemistry and T cell immunology. Our expertise has led to the development of peptide-loaded MHC class I reagents and the refinement of the production of custom pMHC complexes. These complexes encompass over 100 distinct MHC class I and II molecules, including HLA-A, HLA-B, HLA-C, HLA-DR, and H-2 variants.For more information, visit https://immunaware.com/

At Median, we transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for sponsors worldwide. To learn more, visit https://mediantechnologies.com/

MERIT is an oncology endpoint expert providing image collection, centralized reading, and data management services for clinical trials since 2012. We have supported hundreds of trials across 58 countries. MERIT partners with CROs as well as pharma and biotech companies to deliver reliable endpoint services in global clinical trials. To learn more, please visit meritcro.com

Nona Biosciences specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection.

OCCAM Immune is a non-profit Academic Research Organization emerging from Mount Sinai Hospital that provides immune monitoring services for clinical trials. Its streamlined process, from contracting to data delivery, and its one-stop shop approach—from sample processing to assays and data analysis—bridge academic research excellence with industrial scalability. For more information, go to https://occam-immune.com/

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. Its proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphetNSCLC™ test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage. For more information, go to https://www.oncohost.com/

Ozette is a biotechnology company pioneering vertically integrated and computationally-driven solutions for deep immune profiling. By combining advanced AI-driven analysis with high quality & high-dimensional single-cell data generation in our Laboratory, Ozette is transforming immunological insights into actionable knowledge, empowering biopharmaceutical companies to develop precision therapies for complex diseases.

For more information, please visit https://www.ozette.com/

PredxBio, a TechBio company headquartered in Pittsburgh, is powering next-generation cancer therapeutics with its AI-driven spatial biomarkers, which delve into the mechanism of action of drugs and predict patient outcomes with over 90% accuracy. By transforming multiplexed biopsy images and multi-modal spatial data into actionable insights and revealing the network biology of cancer, PredxBio's SpaceIQ platform is setting new standards for biomarker discovery and clinical research. Partnering with top pharmaceutical companies, PredxBio is accelerating drug discovery and advancing personalized medicine to impact over 25 million cancer patients globally. For more information, visit www.predxbio.com.

RadMD is a full service, global imaging core lab for Phase 1-Phase 3.  Our oncology focus means expert, responsive teams who move quickly and are adaptable to your program.   Our industry leading reader group, managed by  medical & scientific affairs team continues to set higher standards for quality and innovation to meet demands of clinical development today. For more information, visit https://radmdimaging.com/

Backed by our brilliant minds, we have turned the traditional CRO model on its head, by fostering a collaborative and personalised approach. Our mission is simple: Solve problems. Deliver quality data. Propel your drug discovery breakthroughs. United by a passion to make sense of complexities and overcome challenges, we apply our specialised knowledge to big-picture thinking. We will explore every option to deliver over and above for your project. We are thought leaders with a deep understanding of immunology, bioassays, molecular biology and a track record of groundbreaking discoveries and novel cell-based tools. For more information, visit https://rouken.bio/

Sino Biological, headquartered in Beijing, China, is a global leader in recombinant protein and antibody production, gene synthesis, and CRO services for life sciences research and drug development. Its facilities include the Center for Bioprocessing (C4B) in Houston, Texas, which specializes in mammalian cell-based protein and antibody production, and SignalChem Biotech (SCB) in Vancouver, Canada, focusing on kinase-related reagents, stable cell line development, and therapeutic discovery. With a U.S. office providing localized support, Sino Biological ensures innovative, high-quality solutions for global academic and industrial clients. For more information, visit https://www.sinobiological.com/

Standard BioTools delivers the leading omics solutions that empower life sciences researchers to discover unique biological insights not accessible by other technologies. Our high-content platforms in affinity-based, spatial and single-cell proteomics and multi-omics offer the highest levels of precision and unique scalability in the life sciences industry. Integration of highly multiplexed single-cell proteomics using CyTOF™ technology with the plasma-based and spatial proteomic modalities of SomaScan™ and Hyperion™ platforms provides characterization of multiple interconnected biological systems and their interactions, leading to a deeper understanding of response and discovery of critical biomarkers that together can form highly predictive signatures. For more information, visit https://www.standardbio.com/

STEMCELL Technologies provides extensive cell culture and isolation tools for stem cell and immunology research. Driven by science and a passion for quality, STEMCELL Technologies manufactures products for immune cell isolation, activation, and expansion to advance cancer research and immunotherapy development. For more information, visit https://www.stemcell.com/

MedQIA, WorldCare Clinical and DARC, have come together to form Voiant, the industry’s leading clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise. Voiant’s unique AI-based software platform integrates all aspects of clinical trial imaging, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data. For more information, go to https://www.voiantclinical.com/

As a global company WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through our unique business models, our integrated, end-to-end services help customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. For more information visit www.advancedtherapies.com.

We are a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, visit https://www.astrazeneca.com/

Headquartered in New Jersey, BeyondSpring Inc. is dedicated to raising the standard of care for cancer patients by developing first-in-class treatments that enhance lives and clinical outcomes for millions of patients in need. Its lead asset plinabulin is a first-in-class selective immunomodulating microtubule-binding agent with dendritic cell maturation activity.  With over 700 cancer patients treated, Plinabulin is being developed as a “pipeline in a drug” for multiple cancer indications with severe unmet medical needs, including extended stage SCLC and metastatic NSCLC with no driver mutation and progressed on prior PD-(L)1 inhibitors. For more information, visit https://beyondspringpharma.com/

Cromos Pharma, a US-based global CRO, delivers cutting-edge clinical research solutions across all trial phases. With access to vast patient populations in 20+ countries, it ensures rapid enrollment and superior data quality. Its unique "No Patients – No Payment" model drives efficiency, reliability, and unwavering commitment to trial success. For more information, visit https://cromospharma.com/

For more information, visit https://diadembio.com/

For more information, visit https://www.egle-tx.com/

Specialized in developing genetically engineered mouse models, GenoBioTX proudly offers an inventory of 9000 catalog mouse models and has successfully customized over 19,000 strains for clients. GenoBioTX also provide more than 600 humanized mouse models for drug discovery. Beyond this, GenoBioTX has expanded into pre-clinical CRO services across diverse disease areas, especially immuno-oncology. Our commitment to innovation and client satisfaction continues to drive our success in the dynamic field of drug discovery. For more information, go to https://www.modelorg.com/en/.

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory, sales & trading, research, and related services to public and private growth companies across multiple focuses and regions. The HCW team has been the leader in the CMPO (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transaction markets since 1998. For more information, visit https://hcwco.com/

Image Analysis Group is a leading imaging Clinical Research Organization, combining medical expertise, a global team and the DYNAMIKA platform with embedded AI capabilities for data management and central review. For nearly 20 years, IAG supports pharma companies in developing novel drugs, using imaging to assess safety and efficacy. For more information, visit https://www.ia-grp.com/about-us/

Delivering the power of T cells to cancer patients. For more information, visit https://immatics.com/

ImmuVia is a biotechnology company pioneering a new class of oncology therapeutics—Cancerlysins™—innovative bispecific antibodies designed to radically improve treatment outcomes while overcoming the limitations of all prior approaches. Our flagship candidate, Cancerlysin IMV-M™, is the first molecule to robustly induce apoptosis in targeted cells without relying on cytotoxic payloads or the internalization of antibody constructs—key limitations of ADCs. As a leader in bispecific antibody development, we are excited to connect with industry experts, researchers, and potential partners at the IO360° Summit 2025. For more information, visit https://immuviatx.com/

IMU Biosciences has developed proprietary platform technologies that generate and translate vast system-level immune data into actionable insights and tools to drive the development of precision medicines across a variety of diseases. Built on over a decade of research at King’s College London and the Francis Crick Institute, IMU leverages advanced immune profiling with proprietary AI and machine learning analytics to uncover novel and actionable clinical immune signatures. For more information, visit https://www.imubiosciences.com/

Myonex integrates clinical trial supply and commercial pharmaceutical services to reduce time, costs, and complexity. Our global presence and expert project management ensure seamless, flexible, and high-quality execution. For more information, visit https://www.myonex.com/

OncoC4, Inc. is a private clinical-stage biopharmaceutical company located in Rockville, MD. Targeting innate and adaptive immune checkpoints to treat cancer and neurodegeneration, OncoC4 actively engages in the discovery and development of novel biologicals by combining an in-depth understanding of immunology with unique designs. For more information, please visit https://oncoc4.com/

At Perceptive, we empower pharmaceutical, biotech, and clinical research organizations to rapidly discover and advance life-changing medicines by delivering unmatched scientific and technological expertise, global operational experience, and end-to-end solutions that ensure confident R&D decision-making. For more information visit https://www.perceptive.com/.

Picture Health creates multimodal AI biomarkers for precision oncology via our proprietary Px Platform with next-generation radiomics capabilities.  Our advanced radiomic and pathomic imaging features, demonstrated in over 80 peer reviewed papers, are tied to interpretable biological tumor characteristics. Picture Health partners with biopharma companies to improve patient characterization & selection using small datasets from Phase 1 and 2 clinical trials. The Px Platform enables us to develop custom predictive AI biomarkers tailored to a specific indication. For more information, go to https://picturehealth.com/

radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organisation, optimising the development of new oncology treatments. radiomics.bio supports biotech and pharma companies in all stages of clinical development offering services including disease characterization, dose impact quantification, response evaluation, image biomarker identification and outcome predictions. With radiomics.bio you can quantify response for objective decision making, obtain early insights from clinical trials, explore and validate drug mechanisms of action, and increase your understanding of disease on a patient, organ, or lesion level for insight-based decision making. For more information, go to www.radiomics.bio

RareCyte provides Precision Biology™ products and services for discovery, translational research and clinical diagnostics. The Orion™ spatial biology platform enables whole-slide highly multiplexed tissue analysis for multiple samples per day. Comprehensive liquid biopsy offerings enable CTC and other rare cell characterization and single cell retrieval for molecular analysis and CDx development. For more information, go to https://rarecyte.com/

Synaptimmune and its partners are leveraging its best in class long acting conditionally active Costimulatory T cell engager platform (TROY-Ig) for targeting Autoimmune diseases and Cancers.

Teiko's mission is to make immune measurement a reality for clinical trials and patients. We use high-dimensional cytometry, both spectral and mass, to measure the immune state of patients on trial in our CLIA-registered lab. We've developed the TokuKit, a whole blood fixation kit, to simplify sample collection, validated 25-40+ marker standard and custom panels across both cytometry platforms, and built a Dashboard with advanced visualization tools for exploring immune composition and kinetics. In short, we make cytometry simple. To learn more, visit teiko.bio

Vicero is a preclinical biopharmaceutical company pioneering the development of next-generation multivalent VHH VINCOBODIES to conquer unmet medical needs in cancer and immunology. The VINCOBODY product engine is proprietary VHH modular technology that enables Vicero to build best in class IO and ADC therapeutics with the potential to address unmet need in the immuno-oncology solid tumor market. Our team of experienced scientists and drug developers has delivered more than 20 life extending therapies to patients in need. For more information, please visit us at www.vicerobio.com or our LinkedIn page